Here we present and evaluate a framework for estimating concentrations of pharmaceuticals over time in wildlife feeding at wastewater treatment plants (WWTPs). The framework is composed of a series of predictive steps involving the estimation of pharmaceutical concentration in wastewater, accumulation into wildlife food items, uptake by wildlife with subsequent distribution into, and elimination from, tissues. As many pharmacokinetic parameters for wildlife are unavailable for the majority of drugs in use, a read-across approach was employed using either rodent or human data on absorption, distribution, metabolism and excretion (ADME). Comparison of the different steps in the framework, against experimental data for the scenario where birds are feeding on a WWTP contaminated with fluoxetine, showed that: estimated concentrations in wastewater treatment works were lower than measured concentrations; concentrations in food could be reasonably estimated if experimental bioaccumulation data are available; and that read-across from rodent data worked better than human to bird read-across. The framework provides adequate predictions of plasma concentrations and of elimination behavior in birds, but yields poor predictions of distribution in tissues. We believe the approach holds promise, but it is important that we improve our understanding of the physiological similarities and differences between wild birds and domesticated laboratory mammals used in pharmaceutical efficacy/safety trials, so that the wealth of data available can be applied more effectively in ecological risk assessments. This article is protected by copyright. All rights reserved
INTRODUCTION
Over the past 15 years, there has been growing interest in the effects of active pharmaceutical ingredients (APIs; parent compound and active metabolites) on ecosystems. APIs are excreted to wastewater by patients, and subsequently can contaminate aquatic and terrestrial environments [1] .
Wild birds may be exposed to pharmaceuticals when they forage on organisms in wastewater treatment plants (WWTPs), soils and surface waters [2] [3] [4] [5] . As biologically active molecules designed to bind to and interact with a specific receptor or process in a target organism, APIs have the potential to cause effects at low concentrations in non-target species, particularly as many of the receptors have been evolutionarily conserved in wildlife [6, 7] . To date, ecotoxicological studies have largely focused on the effects of APIs on algae, invertebrates and fish [8] . In order to protect wildlife, it would be beneficial to develop an understanding of environmentally realistic exposure and potential effects of APIs in other biota such as wild birds and mammals [1, [8] [9] [10] .
When registering an API in the EU and the US, there is currently no legislative requirement to consider secondary exposure, toxicity and risk to wildlife [11, 12] . Only, toxicity to plants, invertebrates (including earthworms) and fish are considered. In the EU, registration of veterinary drugs requires risk assessment of secondary exposure and hazard for wildlife [13] . The models used are based on the European Commission's Technical Guidance Document (TGD) Part II [14] for new and existing industrial compounds. This TGD approach (initially developed for metals and plant protection products) is a simple risk assessment based on daily dietary intake (mg/kg bw) relative to a toxicity reference value [14, 15] . The European Food Standards Agency (EFSA) presents a more advanced methodology than the TGD approach for calculating exposure [16] , but again it is based on dietary exposure rather than internal residues (reviewed in [17] ). In order to gain a greater appreciation of risk it would be beneficial to extend these diet-based models to estimate internal exposure using the wealth of data collected in laboratory mammals and humans during pre-clinical and clinical trials [12, 14, 16] .
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This article is protected by copyright. All rights reserved For example, risks of APIs for wildlife could also be assessed by determining whether plasma concentrations are likely to exceed therapeutic plasma concentrations. For free-living organisms, it may also be more realistic to consider accumulation over multiple low-level daily intakes rather than just a single exposure (typically done for pesticides [16] ), which may under-estimate risk. Concentrations in tissues (particularly sites associated with pharmacological activity) along with diet-based assessments likely give a more robust indication of risk than diet-based toxicity reference values alone.
Accumulation of APIs over environmentally relevant foraging periods (i.e., duration a particular food source or site is used) can be assessed using pharmacokinetic equations to calculate predicted cumulative body burdens at a given elimination half-life (t 1/2 , assuming first order kinetics) [18, 19] .
Alternatively, the theoretical t 1/2 required to accumulate or exceed a threshold (e.g., Human Therapeutic Dose, HTD) can be back-calculated to assess the plausibility of observing such a value in wildlife Lazarus et al [19] . Using pharmacokinetic parameters such as bioavailability (the proportion of the ingested contaminant absorbed from the gastrointestinal [GI] tract) and the apparent volume of distribution (V d , the theoretical volume required to contain the remainder of the dose at the same concentration as observed in plasma), it is possible to estimate plasma concentration for a specific cumulative body burden of an API. Furthermore, concentrations in tissues can be estimated from concentrations in plasma using tissue to plasma distribution ratios. By combining estimated tissue concentrations with t 1/2 , the duration (time) that residues in tissues would remain above quantifiable levels can be estimated to inform field monitoring study design.
Pharmacokinetic parameters, relating to absorption, distribution, metabolism and excretion (ADME), required to run these predictive models have only been defined for a few APIs in wildlife (e.g., the non-steroidal anti-inflammatories diclofenac [20, 21] , meloxicam [22] and ketoprofen [23] ). However, it may be possible to utilize ADME data collected in studies on laboratory mammals and humans that are performed to assess the efficacy and safety of a pharmaceutical, and then to conduct cross-species extrapolation by 'read-across' to predict internal exposure and risk for wildlife. Similar
This article is protected by copyright. All rights reserved interspecific 'read-across' extrapolations have been demonstrated to be suitable for some classes of pharmaceuticals in fish [24] [25] [26] [27] [28] . The application of these approaches for assessing effects in non-target species could be valuable in identifying APIs of greatest environmental concern and for characterizing risks to free-ranging wildlife.
One API that has received considerable attention is the antidepressant fluoxetine, a commonly prescribed selective serotonin re-uptake inhibitor (SSRI). In the environment, fluoxetine is persistent, with monitoring studies often detecting it in water, sediments and aquatic organisms [29, 30] .
Laboratory exposures show fluoxetine to affect behavior of aquatic invertebrates and fish at environmentally relevant concentrations (≥ 0.3 ng/L) [31] [32] [33] [34] . To date, studies in birds on fluoxetine have been principally toxicological in nature [3, 35, 36] , with most attention given to characterizing the uptake and distribution of the molecule in mammals [37] [38] [39] [40] [41] . In the laboratory, starling foraging behavior appears to be altered by fluoxetine at 5% of the HTD [3] . Here we present a predictive framework that used data on API use, metabolism, bioaccumulation in food items and pharmacokinetics in laboratory mammals and humans to estimate internal exposure in wildlife. We evaluate the different components of this approach using field monitoring and ADME data on fluoxetine for the scenario where starlings are feeding on invertebrates in a trickling filter bed of a WWTP.
MATERIALS AND METHODS

Predictive framework for estimating internal exposure
Dietary exposure of birds to APIs may result from foraging in a variety of environments (soils, sediments, surface waters), although greatest exposure is likely to occur during foraging at WWTPs due to the higher concentrations of APIs in these systems. A predictive framework for assessment of dietary and internal exposure of birds foraging on filter beds at WWTPs is presented in Figure 1 .
The predictive framework that follows is presented in full as an editable worksheet in the Supplemental Data. The framework begins by calculating the predicted environmental concentration 
V × P
The mass of a pharmaceutical used by a population can be estimated with data collected on prescribing rates in kg yr -1 (e.g., [42] ). The proportion (≤1) of parent compound excreted by patients can be obtained from the literature or from data held by pharmaceutical companies (e.g., [43] ). The product of M API and Fexcreted was then divided by the product of annual per capita wastewater usage of (i.e., 73,050 L) [44] and the size of the population for which the usage data are available.
The PEC in food (PEC food ) is then calculated by multiplying the PEC wastewater by the bioaccumulation factor (BAF) derived from laboratory studies (Equation 2).
PEC food = PEC wastewater *BAF (2)
A BAF derived for an appropriate species (e.g., earthworms) in OECD-type laboratory studies should be used in preference to predictions based on lipophilicity (e.g., [45] ).
The PEC in plasma (PEC plasma ) of the wildlife is then calculated by adjusting cumulative body burden (CBB, measured in mg/kg body wt) of the pharmaceutical over time (e.g., concentration at peak, i.e. shortly after a meal = zenith, concentration at trough, i.e., just before a meal = nadir) for the fraction of the drug that is bioavailable (F bioav , ≤1) and the apparent volume of distribution (V d , with units of L/kg body wt) [38, [46] [47] [48] (Equations 3a and b).
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The CBB of an API over time is calculated for example at zenith and nadir assuming elimination by first order kinetics (Equations 4a-b) [18, 19] . organism body weight e.g., [49] or from estimates based on observations of foraging behaviour e.g., [50, 51] .
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The duration of exposure is the period of time for which a bird would likely forage at a contaminated site [4, 5] . To estimate CBB over time, equations 4d.i and 4d.ii are used to obtain the fraction of daily intake remaining in the body from prior exposure (DI remaining in body ). 
DI remaining in body
PEC tissue = PEC plasma × R tissue:plasma (5)
As with F bioav and V d , it may be necessary to use information presented in the literature for R tissue:plasma in laboratory mammals and humans (e.g., [37, 38, 52] ).
Post-exposure concentrations in tissue (PEC post-exposure ) are calculated from PEC tissue by continuing the elimination modelling once the animal stops feeding on the contaminated source (Equation 6).
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This article is protected by copyright. All rights reserved Finally, by plotting the data and fitting an exponential trend line (y= Ce -kx ,where C is the y-axis intercept, -k is given by ln(2)/t 1/2 [days] and x is time in days), it is possible to estimate the duration for which quantifiable residues remain in tissues (X LOQ ). An estimate of the time that tissue residues exceed the limit of quantification (LOQ) can be obtained by rearranging the exponential trend line (Equation 7).
(7)
The output from Equation 7 can be used for both interpretation of risk (i.e., rapid clearance below LOQ reduces the likelihood of persistent exposure) and to help inform field monitoring (i.e., which tissues should be sampled to assess internal exposure).
Evaluation of Framework
To evaluate the predictive framework, we used laboratory and field based investigations to generate data to evaluate the different steps in the framework. Observations were then compared with predictions from the framework using input data obtained from the open literature (Table 1) . A description of the validation approach is given below.
PECwastewater and PECfood
To evaluate the PEC wastewater and PEC food , monitoring was done at four trickling filter WWTPs in Northern England in November 2013. At each site, a sample of influent was collected and placed
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This article is protected by copyright. All rights reserved into a 2 L solvent rinsed amber glass bottle. Earthworms (Eisenia fetida) were obtained from the top 20 cm across the filter beds and placed into a clean glass jar. All samples were placed in cool bags containing ice packs and transported to the laboratory. Upon arrival, sludge was rinsed off the earthworms using deionized water. Samples were then frozen at -20°C until extraction and analysis (See Supplemental Data). To evaluate the framework equations, mean measured concentrations (MEC) in influent and earthworms were compared to PECs for influent and food.
PECplasma, PECtissue, PECpost-exposure
To evaluate the framework equations for PEC plasma , PEC tissue and PEC post-exposure , an absorption, distribution and excretion study was done by exposing captive starlings to fluoxetine injected invertebrates wax moth larvae, (Achroia grisella), for 22 wk (see Supplemental Data or [3] ). In total there were 12 males (seven fluoxetine-treated and five controls) and 12 females (five fluoxetine-treated and seven controls). Five mornings per week, the starlings were captured, hand fed one wax moth larvae and returned to their home pen [3] . Fluoxetine-treated birds received a wax moth larvae injected with 1300 ng of fluoxetine (~5% HTD) in 2.5 µL deionized water while controls received a wax moth larvae injected with 2.5 µL deionized water (see Supplemental Data). The dose contained in wax worms was quantified by HPLC (mean ± SE: 1580 ± 73 ng/larvae; see Supplemental Data or [3] ).
Whole blood (0.5 mL) was collected by jugular venipuncture (1 inch 25-gauge needle, 1 mL syringe) after 16 wks of treatment, 1 h after receiving a dose. Blood was immediately transferred to a lithium heparin Microtainer® (Becton Dickinson, UK) and centrifuged for 3 mins at 2000 g. Plasma (~150 µL) was harvested into 1.5 mL microcentrifuge tubes, held at 4°C for <1 h and then frozen at -20°C. Two hours prior to euthanasia, each of the six birds was placed into a cage lined with paper so that feces could be collected to assess concentrations of fluoxetine and metabolites. The feces from each bird were transferred into a microcentrifuge tube, and subsequently weighed, dried at 40°C, ground using a mortar and pestle, and stored in plastic bags at -20°C. Birds were euthanized by cervical dislocation at 
RESULTS AND DISCUSSION
E x p e r i m e n t a l d a t a
A summary of the results of the monitoring and laboratory studies is provided in Table 2 (see Supplemental Data for data on metabolites). Only limited information is available in the literature on the occurrence of fluoxetine in the matrices we investigated. Our measured influent concentration
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Such elementary modelling approaches are dependent upon comprehensive usage data at the catchment scale as well as reliable information on metabolism by patients and other biota, and spatialtemporal variations in flow rates [59] . While information on prescribing rates is available in some countries (e.g., NHS prescription cost analysis in the UK [42] and similar systems are in place in Denmark, Germany and Australia [59] , this may over estimate consumption for some drugs. For example, patients may stop taking medication due to relief of symptoms or adverse side-effects. In western countries, the percentage of households where unused medicines are being 'hoarded' for future use ranges from 1.4 to 65% [60, 61] . For drugs available over-the-counter, prescription data significantly underestimates consumption. Metabolism by patients can also be highly variable between individuals due to factors including age, sex, health status, race and interactions with other medications,
This article is protected by copyright. All rights reserved (e.g., excretion of fluoxetine apparently ranges from 5% [62] to 24% of the dose [43] ). An alternative 'inverse modelling' approach to overcome some of these difficulties has been suggested by Boxall and coworkers [59] ; model input parameters are back-calculated from the MEC and used to calculate PECs in various other scenarios. Using this inverse approach, it seems unlikely that differences in metabolism of fluoxetine could account for much of the 4.4-fold underestimation of MEC that we observed (i.e., F excreted was already set at the upper end of the range, 0.24). The discrepancy is possibly due to underestimation of usage and over estimation of dilution in the environment. PEC plasma : Using the fluoxetine dose administered to starlings and ADME data for rodents, the PEC plasma was between 0.03 and 0.23 ng/mL (nadir-zenith). Use of human ADME data gave a range of 0.44 to 0.50 ng/mL. In the starling study, fluoxetine was not detected in the plasma (LOD = 0.15 ng/mL). It therefore appears that ADME data from laboratory rodents provide better predictions of what will occur in starlings.
The low absorption observed in starlings compared to humans could be due to differences including (i) GI tract pH, (ii) bioaccessibility, and (iii) rapid GI tract transit. Theoretically, differences in GI tract pH could affect bioavailability of a base such as fluoxetine (pKa = 10.06) [63] , which would be protonated (unable to pass through biological membranes well), and therefore poorly lipid soluble in an acidic environment. Starlings have a gizzard pH in the range of 1.6-2.3, which is slightly below the average for the stomach of a satiated human (pH 2.5), but similar to that found in fasted individuals (low of pH
This article is protected by copyright. All rights reserved 1.3). The pH of the avian intestine is typically around pH 6.2 compared with a value of approximately pH 7.0 in humans [64] [65] [66] [67] .
We have previously used in vitro GI tract simulations to examine bioaccessibility of fluoxetine from earthworm tissues [68], but not for the lesser wax moth larvae used in our in vivo experiments.
This work found bioaccessibility of fluoxetine to be lower in birds than mammals; but the 9.6-13.7% difference cannot account for the 2-3 orders of magnitude difference between starlings and humans [68] . Additionally, a preliminary study suggested there was no difference in bioaccessibility of fluoxetine from earthworms that were injected with a solution containing the drug or those that had biologically incorporated it from soil. Wax moth larvae have higher percentage lipid content, lower percentage water content and lower mass (22% lipid and 72.4% water as reported for terrestrial arthropod larvae in [69] , approximate mass ~0.2 g, range 0.14-0.32 g -measured in this study) than earthworms (9% lipid, 83.3% water, approximate mass, mean and range 0.5 g, 0.3-1.0 g [16, 70] ).
However, absolute lipid content (44 mg/larvae vs 45 mg/earthworm) is similar for wax moth larvae and earthworms, which would suggest that bioaccessibilities in the two organisms may also be similar.
Although theoretical and unlikely, the possibility remains that absorption in starlings was very low because of poor bioaccessibility of fluoxetine contained in wax moth larvae.
Low absorption and rapid clearance of fluoxetine from starling tissues could also be due to rapid GI tract transit time. In starlings, invertebrate prey have a GI tract transit time of only 12 mins/g invertebrate and a retention time of 20 mins/g invertebrate [71] . Mean retention time of food in humans ranges from 0.7 to 4 d (mean = 2.3 d) [72] . Hypothetically, such short GI tract transit times could limit absorption of significant quantities of contaminants, conversely birds' relatively high energetic demands and lifespans might increase efficiency of contaminant absorption compared with small mammals. At the time of study design, we were unaware of these data, and suggest others who intend to investigate ADME using small passerines consider GI tract transit time when estimating the likely peak in absorption. An estimate of rapid elimination could also perhaps have been predicted from
This article is protected by copyright. All rights reserved basal metabolic rate (see Supplemental Data Figure S2 ). Thus, we suggest future studies investigating GI tract transit time and API bioavailability are warranted, and far simpler and more economical than measuring ADME. PEC post-exposure : Fluoxetine was rapidly eliminated from starling tissues and detected in less than 50% of samples 26 h post-exposure (Table 2 , compare values at 26 h, 50 h and 74 h with the value at 2 h). It was detected in only one of three liver samples after 50 h, which could be an outlier (possibly due to genetic variation amongst wild-caught birds). Fluoxetine was not detected in any tissue after 74 h.
While data in Table 2 suggest that fecal sampling or cloacal swabs may be a non-invasive method to qualitatively assess exposure (variable rate of excretion and mass produced), destructive sampling to harvest tissues may well be the only option for quantitative purposes.
The rapid clearance from tissues indicates that we are unable to accurately estimate the elimination half-life of fluoxetine. Speculatively, we used the data in Table 2 to estimate fluoxetine t 1/2
This article is protected by copyright. All rights reserved values are actually likely to be 15.6 h, 54.3 h, 40.8 h, and 5.7 h, respectively, which is a reasonable match for all tissues except brain. This illustrates that muscle is not a good matrix to use for monitoring purposes due to a combination of variable elimination in vivo (see Table 2 ) and lower sensitivity of analytical methods for this matrix. Liver and kidney are the matrices where fluoxetine is most likely to be detected, but in brain residues are cleared more than twice as fast as predicted. Applying the predictive framework to free-ranging birds, residues in liver would likely be above LOQ for 39.8 h in liver and 28.9 h in kidney (using t 1/2 of 8.2 h), but only 12.5 h in brain (using t 1/2 of 3.1 h). If the fluoxetine concentration in earthworms was actually at the lower end of the field-measured range, then residues in brain would never exceed LOQ (0.13 ng/g), while at the upper end of the MEC food range for earthworms, residues would still only exceed LOQ for 17.3 h after 22 wk of sustained exposure.
Therefore, if a bird moved away from feeding on the contaminated source for more than 18 h, then for all intents and purposes, its brain could be considered residue free. This narrow window of detection opportunity will certainly make destructive sampling of free-ranging birds difficult to justify.
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Elimination via production of different metabolites than rodents and humans is also a potential explanation for the observed rapid clearance. We investigated production of the active metabolite norfluoxetine and six commonly produced (in humans) inactive metabolites. Norfluoxetine was detected in all tissues 2 h after the final dose (Supplemental Data), but was also eliminated rapidly with Excretion as norfluoxetine accounted for approximately 0.03% of the dose, which was surprising given a mean of 25.6 ng/g in liver (1.38% of the dose/g liver). Norfluoxetine in feces was <LOD in all but two samples (Supplemental Data). Norfluoxetine must either be excreted between 2 and 26 h or further metabolized (See discussion in Supplemental Data). However, we were unable to detect any of the six inactive metabolites (commonly detected in humans taking fluoxetine), which suggests that metabolic pathways are likely very different between starlings and humans. Future ADME studies in wildlife could also benefit from an understanding of interspecies differences in protein binding, membrane transport (e.g., proteins of the cell membrane such as P-glycoprotein) and metabolic pathways (see Supplemental Data [75] [76] [77] ).
If the effects on foraging behavior observed in Bean et al [3] are in fact real, then it is most likely due to subtle neurological changes that result from persistent (months) low level exposure to fluoxetine. If birds are only periodically exposed to fluoxetine (i.e., tissues are cleared for long periods during the winter and breeding season when earthworms are important in the diets of many bird species [78] ), then it is less likely that up/down-regulation of receptors and endocrine related responses could be altered at brain concentrations 3 orders of magnitude below human therapeutic concentration.
Limitations and uncertainties
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The relative sensitivity of the predictive framework to both increases and decreases in fluoxetine concentration in earthworms, mass of food eaten by starlings, F bioav and R tissue:plasma was equal to 1 at both nadir and zenith (see editable framework in Supplemental Data 2). The relative sensitivity to t 1/2 and V d differed depending on context; at nadir, changes in t 1/2 were amplified by the framework (for decreased values, R was up to 2.3, and for increased values, R was up to 2.7), whereas at zenith, However, in the present study PEC food and MEC food for fluoxetine happened to be well matched.
Second, the foraging behaviors of free-ranging birds can be quite variable; this could affect the extent to which individuals routinely ingest earthworms contaminated with pharmaceuticals. Third, in terms of pharmacokinetics it would be beneficial to know V d and F bioav for multiple APIs and how the physiologies of birds relate to laboratory mammals. Fourth, overestimation of CBB zenith and underestimation of CBB nadir would result from assumptions that the dose is taken up in a single meal. In reality, many species feed throughout the day and are often opportunistic (gorge themselves). Finally, once APIs are distributed into liver, some fraction may end up in bile, re-enter the intestine and blood stream, and return to the liver (entero-hepatic recirculation [82] ).
This article is protected by copyright. All rights reserved Uncertainty in the framework was greater at nadir than zenith. Using the 27 different combinations of input parameters, mean ± SE brain concentration at nadir was 0.47±0.13 ng/g (CV=146.2%) and zenith was 2.70 ± 0.47 ng/g (CV= 90.5%). However, uncertainty could be reduced at nadir to, 0.58 ± 0.13 ng/g (CV = 117.1%) and at zenith to, 3.35 ± 0.39 ng/g (CV= 60.9%) by excluding fluoxetine concentrations at one of the four WWTPs where values were much lower. While the CV is relatively high, it is important to view this uncertainty analysis in perspective (i.e., describing relative change in the low ng/g to pg/g concentration range). Therapeutic effects of fluoxetine in humans and laboratory mammals are only found at µg/g levels. Thus, the uncertainty of the framework does not change the conclusions about the likelihood of adverse effects. It is important to acknowledge that this is a preliminary framework upon which we hope others can build and integrate in ecological risk assessment.
The present framework illustrates that substituting rodent fluoxetine ADME data for starling ADME data predicts low absorption and rapid elimination, but markedly overestimates distribution into brain. Nonetheless, predicted internal concentrations are still within a few ng/g of measured internal concentrations in experimentally dosed starlings. If we had compared our starling ADME to that of humans, the low absorption of fluoxetine by starlings and absence of accumulation after such an extended dosing period would have been problematic. However, using rodent ADME and inverse modelling to calculate PEC tissue for starlings that were chronically dosed at 5% HTD, we would expect residue levels to be 1000 times less than the therapeutic concentration.
Data needs
In order for interspecific pharmacokinetic extrapolations to work as a predictive framework for internal API concentrations in wild birds, we must gain a better understanding of the physiological and pharmacological differences between wild birds, mammals and humans. For example, estimates of PEC plasma could be improved using a combination of in silico (literature review of current knowledge on interspecific differences in GI tract physiology), in vitro (assessments of bioaccessibility [68] ,
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Supplemental Data for discussion) and in vivo approaches (intravenous injection compared with oral to assess bioavailability, define plasma concentrations at higher doses than environmentally relevant concentrations to exceed LOD). It would be feasible to determine absorption (compare plasma uptake curve between oral and intravenous administration) and distribution into key sites of pharmacological activity. It would be beneficial to identify and conduct these in vivo assessments in several model wild bird species that could be considered representative of key Orders of birds likely exposed to APIs (e.g., passerine, waterfowl, gallinaceous birds, corvids, gulls and even raptors). To ensure the eliminationcurve can be captured, post-exposure time-points should be limited to 24 h, rather than 74 h as used herein.
Once the predictive framework is validated for one exposure pathway, the next challenge is to expand the scope of the framework to include uptake of multiple APIs in various food webs (e.g., plants/fruits/ seeds grown in soil amended with sludge, aerial insectivores above WWTPs, wading birds in estuarine sediments). Field measurements of APIs soils, sediments and aquatic environments as well as the wildlife food items that grow and develop therein, could enable estimation of BAFs. These could be applied to expand the predictive framework. It will also be important to understand the extent to which individuals rely on contaminated sources for nutrition. This could be achieved through observations [4] , remote tracking methods [83] and next generation sequencing of fecal samples (e.g., [84] ).
CONCLUSIONS
Dietary exposure of wild birds to APIs is plausible, but at present there is limited quantitative evidence to support this assertion, and even less for estimating hazard and risk. Gaining an improved understanding of API ADME for wildlife, and its relation to rodent and human ADME is important.
This would enable the use of a wealth of information on effects of APIs gathered from pre-clinical and clinical trials for the conduct of ecological risk assessments.
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